Psoriasis Treatments

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

The company moves to raise $175 million following the readout, signaling plans for an FDA filing in the second half of 2026.